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Abstract
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease in which an immune-
mediated injury targets the small intrahepatic bile ducts. PBC is further characterized by highly
specific serum antimitochondrial autoantibodies (AMA) and autoreactive T cells, a striking female
predominance, a strong genetic susceptibility, and a plethora of candidate environmental factors to
trigger the disease onset. For these reasons PBC appears ideal to represent the developments of the
clonal selection theory over the past decades. First, a sufficiently potent autoimmunogenic
stimulus in PBC would require the coexistence of numerous pre-existing conditions (mostly
genetic, as recently illustrated by genome-wide association studies and animal models) to
perpetuate the destruction of the biliary epithelium by the immune system via the persistence of
forbidden clones. Second, the proposed modifications of mitochondrial autoantigens caused by
infectious agents and/or xenobiotics well illustrate the possibility that peculiar changes in the
antigen structure and flexibility may contribute to tolerance breakdown. Third, the unique
apoptotic features demonstrated for cholangiocytes are the ideal setting for the development of
mitochondrial autoantigen presentation to the immune system through macrophages and AMA
thus turning the non traditional mitochondrial antigen into a traditional one. This article will
review the current knowledge on PBC etiology and pathogenesis in light of the clonal selection
theory developments.
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The clonal selection theory and the history of biliary autoimmunity
Two remarkable insights in 1948 and 1957 by Frank Macfarlane Burnet were to set the
course for modern immunology 1, 2. In 1948 he deduced the nature of immunological
inertness to self, named this as “tolerance” and proposed it to be a characteristic acquired in
developmental life rather than innate as earlier believed 3. His intuition led to seminal
consequences in our understanding of autoimmunity. First, in 1957 (while the hypothesis
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was elaborated in19594) he proposed that specificity of antigen recognition existed in cells
of the immune system before any exposure to antigen for which the role was to select cells
for clonal proliferation rather than acting in any “instructional” way to do so. Second, these
concepts coincided closely in time with the renaissance of the notion of autoimmunity, in the
late 1940s, so leading to the idea that an event such as a somatic mutation among cells of an
antigen-stimulated clone could result in an aberrant proliferative response to a self antigen.
This, together with a resistance to an ill-defined immunological homeostasis, could result in
a ‘“forbidden clone” as the basis for an autoimmune disease 4. The ‘forbidden clone’
hypothesis was elaborated in our monograph of 1963 2, and still retained by Burnet in 1972,
but developing knowledge in the 1960s including the B and T cell dichotomy and other
advances left the concept increasingly harder to sustain. In particular, T lymphocytes do not
undergo post-diversification mutations of their antigen receptor (TCR) whereas
hypermutagenesis of genes for the B cell receptor (BCR) in germinal centers of lymph nodes
is normally required for affinity maturation, and presumably gives rise constantly to self-
reactive BCRs, but such cells for various reasons, including, lack of T-cell help, fail to
thrive.
Also many advances were made in the 1960s on the expressions of autoimmunity among
which was recognition of two separate albeit overlapping groups of diseases, “organ-
specific” (prototypically lymphocytic thyroiditis) in which the identifiable autoantigens
(named traditional) were constituents of the affected tissue, and “multisystemic”
(prototypically systemic lupus erythematosus -SLE) in which the identifiable autoantigen(s)
(non-traditional) were distributed in all cells throughout the body. This latter group includes
the clinically, histologically and immunologically well-defined liver disease primary biliary
cirrhosis (PBC) wherein there is consistent reactivity with a mitochondrially located
autoantigen recognized over some 50 years as eliciting antimitochondrial antibody (AMA)
reactivity, and researched from many angles over the past 25 years in our laboratory, as
described in this encompassing review. In general terms, the 2010 products of the seminal
evidence proposed by Frank Macfarlane Burnet of mutagenesis as the major feature of
immune degeneration leading to autoimmunity is the objective of this Special Feature issue
to celebrate the 50-year anniversary since the Nobel Prize was awarded for the enunciation
of immune tolerance.
The first description of possible biliary cirrhosis, probably obstructive, was by the celebrated
Italian pathologist Giovanni Battista Morgagni in 1761 and the earliest report of non-
obstructive biliary cirrhosis is attributed to Addison and Gull in 1851 5. The disease was put
on the map clinically by Ahrens et al in 1950 6. Serum “anti-tissue” autoantibodies were
described in 1959 and PBC was nominated as an autoimmune disease in 1963 4. The anti-
tissue autoantibodies were identified as antimitochondrial in 1965 7. After a considerable
pause, a cDNA encoding the AMA autoantigen was cloned in 1986 and the antigen was
identified as subunits (E2) of the pyruvate dehydrogenase complex (PDC) 8, 9 is nuclear
encoded and expressed but is imported to become located on the inner mitochondrial
membrane.
In the wider field of autoimmunity numerous self antigens became recognized as functional
structures of the cell, particularly nuclear components, the autoepitopes were mapped, but
adverse effector/inhibitory properties of autoantibodies in vivo remained incompletely
defined 10. Among the characterized autoantigens, functional sites were found within cell
nuclei as chromatin, nucleoli and ribonucleoproteins additional to the mitochondrial
proteins. DNA molecules and the associated histones were among the most common of the
reactive nuclear autoantigens, being recognized by almost all sera from patients with SLE
giving reactivity for ANA. Other ANA included anti-Scl70 antibodies directed against
topoisomerase I (Scl-70), a nuclear non-histone protein that uncoils condensed chromatin
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during mitosis 11, the anti anti-Sm 12 antibodies, and SS-B (or La) antibodies directed at
eukaryotic RNA polymerase III in Sjögren’s syndrome and SLE. The genesis of all of these
“non-traditional” autoantibodies seemed harder to explain than that of the “traditional”
autoantibodies of organ-specific autoimmunity such as thyroid peroxidase (TPO) and
thyrotropin receptor (TSHR) recognized by autoantibodies in autoimmune thyroid diseases.
The discovery of PBC-specific antinuclear antibodies (ANA) came after AMA description
and led to further possible implications in the pathogenesis of the disease, although our
knowledge on the ANA onset and role in PBC remains largely incomplete. We will herein
provide a conspectus of mitochondrial autoimmunity before returning to the question of how
clonal selection theory might relate to the non-traditional, if not paradoxical, autoimmunity
of PBC by invoking our recent discoveries on patterns and pathways of apoptosis in the
target cell, the cholangiocyte.
Biochemical properties of the PBC autoantigens
The 2-OADC autoantigens are multi-enzyme complexes essential in energy metabolism
13.Since this enzyme family has been repeatedly reviewed in the context of PBC, the data
are presented in summary form in Table 1 and Figure 2 for the constituent pyruvate
dehydrogenase complex (PDC), the 2-oxo glutarate dehydrogenase complex (OGDC), and
the branched chain 2-oxoacid dehydrogenase complex (BCOADC). Each of the three
complexes consists of three subunits, i.e. E1, E2 and E3. The E2 components consist of
several functional domains. There is the inner catalytic domain containing the active site,
one or more lipoyl domains containing the lysine residue to which the essential cofactor
lipoic acid is attached, and an E3-binding domain. PDC-E2 and E3BP are the major
autoantigens for serum AMA. Both PDC-E2 and E3BP fold into distinct domains linked by
flexible regions rich in alanine and proline residues; interestingly, such flexibility is
important for the enzyme catalytic function 14. Moreover, both polypeptides have a central
core region, responsible for binding to other polypeptides. The E2 core, moreover, contains
residues essential for its catalytic activity and is linked to a binding domain, which accounts
for the binding to E1 (and possibly E3). On the other hand, the corresponding E3BP region
binds E3 only. Both polypeptides include at their amino terminals compact domains
containing the covalently attached lipoic acid co-factor 13. PDC-E2 has two and E3BP a
single lipoylated domain 15. These lipoyl domains are exposed on the surface of the E2 core,
a necessity for the function of the molecules. In all three instances, the domain is composed
by a single lipoic acid residue covalently attached to a lysine residue in a constant DKA
sequence motif. There are no crystallographic structural data but there is available for the
inner lipoyl domain of human PDC-E2 a three dimensional model derived by nuclear
magnetic resonance (Figure 1)16.
Antigen-specific adaptive response in PBC
AMA specifically recognizes lipoylated domains of the 2-oxoacid dehydrogenase (2-
OADC) family of enzymes (Table 1) of the mitochondrial respiratory chain. All
immunodominant epitopes contain a ExDKA (glutamic acid –E-, x, aspartic acid, -D-, lysine
–K-, and alanine –A-) motif, with lipoic acid attached to K at position 173, which is
necessary and/or sufficient for antigen recognition 17. Amongst the 2-OADC constituents,
the major autoantigen is the E2 subunit of pyruvate dehydrogenase complex (PDC-E2). Less
frequent autoantigenic are the E2 components of 2-oxo glutarate dehydrogenase (OADC-
E2) and branched-chain 2-oxo acid dehydrogenase (BCOADC-E2) complexes and the E3
binding protein (E3BP) 8, 18. In addition, nucleotide sequence analysis of genes encoding
specific human monoclonal antibodies to PDC-E2 and combinatorial Fabs strongly suggest
that these autoantibodies have been selected from a restricted set of somatically mutated
immunoglobulin germline genes.
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T helper (CD4+) TCR αβ+ and CD8+ T cells are present in portal tracts, around damaged
bile ducts, strongly suggesting the participation of cellular immune mechanisms in the
biliary damage 19–26. Autoreactive CD4 T cells that specifically target PDC-E2-self-antigen
are present in peripheral blood and liver. There is a specific 100–150 fold increase in
number of PDC-E2-specific CD4 T cells in the hilar lymph nodes and liver versus peripheral
blood in patients with PBC 21, while it is of interest that their presence is independent of the
serum AMA status 22. Autoreactive CD8 T cells likewise have been characterized in PBC,
and are considered the major effectors of tissue injury in PBC. The HLA class I restricted
epitope for CD8 T cells, namely the 159–167 aa sequence, maps in close vicinity to the
epitopes recognized by CD4 T cells as well as by AMA (Figure 2). Notably the autoepitope
for T cells, both CD4 and CD8 T cells, overlaps with the B cell (AMA) counterpart and
includes the lipoylated amino acid K173 of the inner lipoyl domain. Similar to CD4
autoreactive T cells, there is a 10-fold higher frequency of PDC-E2 159–167 specific CD8 T
cells within the liver versus peripheral blood Moreover, the precursor frequency of PDC-E2-
specific autoreactive CD8 T cells is significantly higher in early rather than late stage of the
disease. The autoreactive CD8 T cells in PBC have specific cytotoxicity against PDC-E2
antigen and, as well, produce IFN-g rather than IL-4/IL-10 cytokines 27.
The role of lipoic acid in PDC-E2 recognition
The three-dimensional model of PDC-E2, and its unique oxidative mechanisms, raise the
idea that foreign compounds that mimic or alter lipoic acid could bind AMA when the lipoic
acid molecule becomes conjugated to any carrier molecule, such that immunization of
rabbits with a bovine serum albumin (BSA) conjugate of a lipoic acid mimic (6-
bromohexanoic acid) would induce AMA28, and it was later demonstrated that lipoic acid
can indeed be mounted on a protein background 29. Thus PBC could be due to chemical
exposure, and lipoic acid or a lipoic acid mimic could be important in failure of tolerance to
mitochondrial antigens 28, 30, 31. Several lipoic acid (IA) mimotopes have been identified
with the use of mimotope conjugated carrier molecules and affinity purified anti-PDC-E2
antibodies; specifically, 79/97 (81%) of AMA-positive PBC sera reacted to lipoylated
human albumin (HSA-LA), and a high reactivity to HSA-LA correlated with the level of
reactivity to PDC-E2. Also, PDC-E2 affinity purified sera reacted with HSA-LA, suggesting
that some of the antibodies to HSA-LA are a subset of anti-PDC-E2 specificities. The
antibody reactivity to lipoylated PDC-E2 and PDC-E2 is predominantly IgG and IgM
whereas that to HSA-LA is predominantly IgM. Bruggraber and colleagues 17 have
demonstrated the presence in sera of patients with PBC of (a) antibodies with specificity
against PDC-E2 that are capable of recognizing both PDC-E2 and lipoic acid and (b)
antibodies to lipoic acid that recognize a conjugated form of lipoic acid but not the PDC-E2
backbone. Notably, antibodies to PDC-E2 LA and antibodies to lipoylated peptide
conjugates are not merely cross-reactive antibodies: they differ in their epitope specificity
and also in their Ig subclass and affinity for antigens. Previous studies had failed to detect
anti-lipoic acid antibodies when free lipoic acid was used as an antigen 32, yet our findings
otherwise on the presence in PBC of autoantibodies to lipoic acid 17 are of particular interest
in resembling the immune response to iodine in autoimmune thyroiditis observed in
chickens, rats and NOD mice 33–37.
Cholangiocyte apoptosis and “traditional” mitochondrial autoantigens
The mitochondrial antigens recognized by both B and T cell autoimmune responses in PBC
are ubiquitously expressed in all nucleated cells, and are highly conserved in phylogenesis
38. Mitochondrial 2-OADC antigens are not “cryptic” to the immune system, and normally
there is tolerance to these, even if there are responses to bacterial homologs which are
phylogenetically distant from human proteins. During spontaneous or induced apoptosis,
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numerous---perhaps all--- cell types express mitochondrial antigens on the intact plasma
membrane and within apoptotic blebs 39, 40 which then acquire the capability to initiate an
autoimmune response by presentation of 2-OADC-derived autoantigens 41. Notably this
latter process is specific to cholangiocytes, explaining in part why PBC recurs after liver
transplantation 42, 43. Indeed, AMA may react, though weakly, against biliary epithelial cells
of normal subjects 44 and specifically reactive T cells45, 46, and B cells, and serum AMA 47,
have been found (at low levels) in the serum of non-PBC subjects. Nevertheless, the
immune system starts a progressive autoimmune attack against cholangiocytes only in
patients destined to develop PBC, and this occurs irrespective of whether the biliary
epithelium is derived from a patient with PBC or a control subject 48. Accordingly, liver
infiltrating autoreactive T cells to 2-OADC were found only in patients with PBC49,
irrespective of their serum AMA status 22. The mitochondrial autoantigens undergo a
particular cell-specific processing that may well contribute to, if not entirely explain, the
organ specificity of PBC 50, 51. The lack of putative post-translational modifications alters
protein degradation leading to the accumulation and exposure of large amounts of
autoantigens, as postulated for the “traditional” autoantigens of the organ-specific
autoimmune diseases 52. In most cell types, lysine-lipoylated sequences when released from
mitochondria during apoptosis 50 are oxidized by glutathiones; the oxidated forms are not
immunogenic and are not recognized by serum AMA because glutathionylation masks the
autoantibody recognition site 50 53. On the other hand, cholangiocytes and cells from certain
other epithelia fail to covalently link glutathione to lysine-lipoyl groups during apoptosis 50.
In cholangiocytes cleavage of the immunodominant PDC-E2 epitope has not been detected
in vivo during either apoptosis 50, 54 or phagocytosis 55. Moreover, the enhanced expression
of 2-OADC proteins, with a particular luminal concentration, is seen early in cholangiocytes
in PBC versus other chronic inflammatory biliary disease e.g. primary sclerosing cholangitis
44. This abnormal expression of PDC-E2 may depend on self-antigens being presented by
cholangiocytes after binding to HLA molecules, although HLA class II on cholangiocytes
have more an intrahepatic basolateral than luminal surface expression 56–60 and anyway, are
expressed only weakly and in the early stages of disease 60. This observation could be also
secondary to immune complexes deposition rather than membrane protein expression. There
are different opinions on exposure of self-antigens on the cell membrane during
cholangiocyte apoptosis 39, 50, or during the rearrangement of lipid rafts as seen after TLR
activation by microbial infection 61 or after ingestion of apoptotic cholangiocytes by other
cholangiocytes 55. Whilst cholangiocyte phagocytosis of neighboring apoptotic
cholangiocytes is not specific to PBC, this effect could be involved in the presentation
process of mitochondrial antigen observed in PBC indicating that mitochondrial
autoantigens are similar to the ‘traditional’ group.
The intact PDC-E2 in apoptotic fragments could be uptaken by local antigen presenting cells
and transferred to regional lymph nodes for priming of cognate T cells thus initiating PBC.
This is indeed an attractive possibility, however solid data of such antigen presentation are
awaited and it could not be excluded that the reported mechanisms are not PBC specific. A
major contribution came from Lleo and colleagues who first demonstrated that PDC-E2 is
found in the blebs of human intrahepatic bile duct cells undergoing apoptosis 40 and
subsequently that macrophages are capable to uptake the autoantigen found in apoptotic
blebs (coined apotopes) 41. The addition of serum AMA to the coculture of macrophages
and apotopes led to a significant increase in proinflammatory cytokine secretion. These
phenomena were not observed in other epithelial cell lines and appears to confirm the
importance of apoptosis in the perpetuation of the autoimmune injury 62 as well as the view
that PBC bile duct cells are not unique 48.
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Antinuclear antibodies (ANA) in PBC
Serum ANA are detected in nearly 50% of patients with PBC with some reports suggesting
that the prevalence may be higher in AMA-negative sera 63 PBC-specific indirect
immunofluorescence patterns include ‘nuclear rim’, based on the recognition by the
autoantibodies of gp210 and nucleoporin 62 (within the nuclear pore complex which also
includes LBR) and ‘multiple nuclear dots’, based on the reactivity with Sp100, PML, and
most recently, Sp140 (nuclear body proteins) 64, 65. In addition, the cross-reactivity with
small ubiquitin-like modifiers (SUMO) bound to both Sp100 and PML have been suggested
as independent antigens also specific for PBC 66. The prevalence of ‘nuclear rim’ ANA in
PBC is similar with the different techniques utilized for the test, particularly when
recombinant or isolated antigens are included. Gp210 consists of three main domains: a
large glycosylated lumenal domain, a single hydrophobic transmembrane segment and a
short cytoplasmic tail. The antigenic epitopes recognized by anti-gp210 ANA are located
within the glycosylated lumenal domain (a 64 kD fragment) and the cytoplasmic tail (15
amino acids) 67. In general terms, anti-gp210 are detected in 26% of cases using the gp210-
C terminal peptide a.a.1863–1887 68 and 27% when using isolated nuclear pore complexes
69. The major nuclear body protein is Sp100 which consists of at least three non-overlapping
major autoantigenic domains in sp100 recognized by Sp100 positive PBC sera and two
stretches of 16–20 amino acids are the predominant autoepitopes 67. One domain, which
contains the sequence similarity with HIV nef proteins, was recognized by all anti-sp100
sera. The prevalence of anti-Sp100 ANA in PBC is estimated to range between 9% 68 and
30% 70 when different methods are used. It was first supposed that ANA-positive patients
with PBC are more frequently AMA-negative, possibly because of the lack of a masking
effect of these latter antibodies in such sera, yet this remains to be determined and current
data do not support this view.
There is a third type of ANA associated with PBC and are directed against centromeric
proteins (ACA) that occur in PBC mostly together with the usual “clinical partner” of ACA,
limited CREST-type scleroderma, at a prevalence formerly cited as 10% 71 but now
seemingly higher 68, although with specificity limited by the rheumatological comorbidity.
No studies have been able to discern any link between PBC-specific ANA or the antigens
they recognize and the immunopathology of PBC, nor it is clear how or why these ANA are
generated in individuals with PBC. Whether ANA-positivity should be regarded as the result
of the unique cholangiocyte apoptotic features (discussed below) or of the T regulatory
defect 72 is a fascinating hypothesis that awaits experimental confirmation and provides
additional evidence that ‘nontraditional’ autoantigens in PBC could in fact be ‘traditional’.
Nevertheless, significant associations between the presence of ANA and a worse prognosis
have been independently reported 73, 74, different from AMA 75.
Innate immunity in PBC
Innate immunity as an activator of autoimmune responses is receiving much attention 76.
The liver is a major organ of innate immunity in containing the largest resident population of
innate immune system cells, including NK and NKT cells. As with other autoimmune
diseases innate immune mechanisms likely contribute to the initiation and progression of
liver damage 77, and in PBC in particular as judged by features such as epithelioid
granulomas, elevated levels of polyclonal IgM, hyper-responsiveness of the immune system
to CpG, increased levels in blood and liver NK cells 78 and an indicative cytokines response
77. There is a consistent elevation of serum polyclonal IgM in PBC, regardless of the AMA
or ANA status 79, and reduction is usually observed during treatment 80. The hyper-IgM
appears secondary to a chronic innate immune response of memory B cells to specific
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bacterial molecular motifs such as unmethylated CpG motifs 81. Furthermore patient
peripheral B cells exposed to CpG motifs express increased amounts of TRL9 and CD86 so
enhancing their production of AMA. This evidence strongly suggests a profound disease-
specific dysregulation of B cells and supports the proposed link between bacterial infection
and PBC i.e. B cells become hyper-responsive to innate stimuli, such as microbial CpG
motifs, favoring perpetuation of the autoimmune process 82. Other innate immune cells such
as monocytes have also been implicated in the pathogenesis of PBC since their pro-
inflammatory activity is greatly enhanced in PBC. Functionally, monocytes become
activated by pathogen-associated patterns through TLR to release pro-inflammatory
cytokines, including IL-1, IL-6, IL-18, IL-12, and TNF-α that can amplify adaptive T cell
mediated immune responses against pathogens 83. Thus peripheral blood monocytes in PBC
are overly sensitive to infectious stimuli resulting in hyper-secretion of pro-inflammatory
cytokines; the relevant mechanisms are unknown but might relate to the higher frequency of
recurrent Gram-negative bacterial infections (e.g. urinary tract infections) in PBC. In other
words both B cells and monocytes constantly exposed to bacterial products from portal
blood could participate in the modulation of adaptive cellular immune response and possibly
also in its priming.
NKT cells are now implicated in autoimmunity84 as innate effector cells which are regulated
by self and non-self glycolipid antigens presented by the antigen-presenting molecule CD1d,
allowing for a rapid NKT cells production of effector cytokines and chemokines, thus
modulating both innate and adaptive immune responses. The involvement of NKT cells in
the pathogenesis of PBC was suggested by our study reporting a higher than normal
frequency of CD1d-restricted NKT cells in PBC patients and, as for autoreactive T cells,
CD1d-restricted NKT cells were more frequent in liver than peripheral blood 26. Chuang et
al. found likewise an increased number of CD1d-restricted NKT cells in the liver of a mouse
model for PBC transgenic for directed expression of a dominant-negative form of TGF-beta
receptor type II (dnTGFβRII). Such CD1d-restricted NKT cells in the liver had an increased
IFN-γ production after exposure to α-galactosylceramide (α GalCer) and there was a
decreased hepatic lymphoid cell infiltration and milder cholangitis than in controls 84 Innate
immune system hyper-responsiveness is probably insufficient per se for disruption of
immune tolerance, might well participate in the initiation and/or perpetuation of
autoimmune injury. Thus Mattner et al demonstrated that, in a murine model of PBC
(discussed below), N. aromaticivorans induced autoreactive AMAs and T cell-mediated
autoimmunity against small bile ducts via NKT-dependent mechanisms 85.
Environmental agents and PBC autoantigens
Environmental agents, chemical compounds or infecting microbes, are suspected to be
involved into the breakdown of tolerance, through molecular mimicry and cross reactivity
mechanisms 86. This idea is supported by the less than complete genetic evidence including
~60% concordance rate for PBC in monozygotic twins 87 and insufficient associations in
PBC patients from genome wide association studies 88, 89. Thus a mimotope carried by a
microbe or a neo-antigen generated by xenobiotic-modified self-antigen that mimics
mitochondrial proteins may activate autoreactive lymphocytes that have “leaked out” into
the peripheral repertoire.. The process becomes self-perpetuating because of the presence of
cross reactive unmodified self-antigens on cholangiocytes surface.
Similar to the majority of autoimmune diseases and their specific autoantibodies, the
pathogenetic role of serum AMA remains debated and data questioned the sequence of the
immunodominant B cell epitope and the role of the lysine-lipoylated motif in the PBC B cell
response 90. Ultimately, only the recapitulation of an AMA-mediated injury in an animal
model will provide definitive evidence of the autoantibody role in PBC pathology 91.
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However, the study of the immunodominant T cell epitope, PDC-E2 163–176, has provided
important evidence on pathogenesis of PBC, based on the reactivity of cloned PDC-E2 163–
176-specific T cell lines. Thus, for this peptide, the contact residues with T cell receptors
(TCRs) are 168 EIExDK173 so that microbial proteins, whether or not related to PDC-E2,
that have an ExDK sequence are potentially capable of recognition by autoreactive T cells.
Interestingly, this activating PDC-E2 peptide was not lipoylated at K173 and conservative
substitutions at position 173 did not abrogate T cell response, indicating that the lysine-
lipoylated motif is a minor role participant in T cell responsiveness. However glutamic acid
(E)170 is crucial to T cell recognition as its substitution abrogates reactivities. Considering
the proximity of E170 to K173 (Figure 2), we hypothesize that the customary
glutathionylation of the lysine-lipoyl residue at position 173 can mask or alter the exposure
of E170 so as to abrogate contact between this residue and CDR3 of the TCR. Of note, this
mechanism can be considered as an “immunologic defense” in most cell types with the
exception of cholangiocytes 17. The experimental evidence illustrated thus far (along with
the demonstration of autoantibody reactivity with lipoic acid) has obvious fascinating
implications in terms of autoantigen selection. Indeed, one of the major issues in classical
immunology is what makes an antigen an autoantigen. Indeed, this commonly takes place
for intracellular enzymes (as in the case of PBC) and cell surface receptors. While molecular
mimicry and epitope spreading (discussed below) cannot be overlooked, additional
mechanisms have been sought and currently imply the structural features of antigens,
particularly flexibility, as well illustrated by the three major type 1 diabetes autoantigens 92,
93. Other factors may also include dysfunctions of vitamin D 94 based on genetic
polymorphisms 95 or other modulators 96.
Infectious agents
The question of an environmental factor initiating PBC 97, this is supported by the
incomplete concordance among monozygotic twins 87, there are reported instances of non
familial clustering 98–100, and a claimed changing risk of PBC in individuals moving from
high risk to lower risk locations (i.e. geoepidemiology) 101, 102 103, 104. Infectious agents are
the obvious choice for environmental candidates and support for an infectious hypothesis is
garnered from data that lipopolysaccharide (LPS), a specific component of gram negative
bacterial cell wall, injected into mice either alone or in combination with PDC-E2 induce the
appearance of portal lymphocytic infiltration and cholangiocyte degeneration as seen in the
human PBC liver. Further, lipoteichoic acid (LTA), the gram positive cell wall component,
has been detected in PBC liver samples around damaged bile ducts, and serum levels of
LTA-specific IgA are significantly higher in PBC than in normals 105, and bacterial DNA
containing unmethylated CpG motifs triggers a PDC-specific Th1 response in PBMC from
mice immunized with PDC 106. Finally, Th17 cells that are important components of the
mucosal host defense system against infections (although also involved in the pathogenesis
of various autoimmune diseases 107), are constituents of the periductular infiltrates in human
PBC 108, 109. However, the identity of the suspected pathogen (if such does exist) and the
exact initiating mechanisms remain unrecognized.
Among mechanisms proposed to explain just how an infectious agent could contribute to the
onset of an autoimmune disease in genetically susceptible subjects, molecular mimicry
remains popular, having been reported for many microbes 110. Shared sequences between
human and microbial proteins can disrupt immune tolerance by inducing cross reactive
antibodies or effector T cells and/or by promoting epitope spreading 111, although this has
been refuted in PBC 112. Other non-exclusive mechanisms involve superantigen polyclonal
activation of T cells, i.e. staphylococcal enterotoxins 113, mouse mammary tumor virus
antigens 114 and viral polyclonal activation of B cells, i.e. Epstein Barr virus 115, IgA
production, and Th17 differentiation.
Selmi et al. Page 8
Immunol Cell Biol. Author manuscript; available in PMC 2011 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
We may summarize that numerous specific infectious agents, mainly bacteria, but also
viruses, parasites, and fungi, have been suspected in PBC 116, but these studies have failed
to demonstrate any clear association of a microbial agent with the disease and the evidence
at best is only circumstantial, such as linear or conformational mimicry between microbial
proteins and human mitochondrial antigens.
Xenobiotics
The other environmental factor seriously proposed for is constituted by foreign chemicals
i.e. xenobiotics that can modify a defined self or non-self protein so as to cause a change in
its molecular structure that enhances immunogenicity. This has been proposed for numerous
autoimmune diseases and is consistent with the observed geoepidemiological gradient 117–
119 and is supported by a number of epidemiology studies as previously discussed. One
particular example is development of autoantibodies in subjects to halothane, a previously
used inhalatory anesthetic that can induce antibodies reactive with lipoylated PDC-E2 120.
As stated above, lipoic acid attaches to only a very limited number of proteins, yet is a
critical component of the PDC-E2 epitope 17. The PDC-E2 structure exposes lipoic acid at
the exterior of the protein complex making it accessible to chemical modification 29. The
role of xenobiotics in PBC is supported by serum reactivity against specific organic
compounds with structures similar to lipoic acid 121; further, two of these compounds (6-
bromohexanoate and 2-octynoic acid) are capable of inducing AMA and PBC-like liver
lesions in guinea pigs 122 and NOD.1101 123 or C57BL/6 124 mice, respectively. The ability
of N. aromaticivorans to metabolize chemical compounds might link xenobiotics and
bacteria in the etiology of PBC, as discussed above.
The 2-OADC antigens undergo several post-translational modifications endogenously, and
such changes may alter the epitope regions of the proteins. Nevertheless, external influences
can also contribute to protein alterations and neo-antigen formation 51. Of note, the liver is
constantly exposed to chemicals derived from the gut through the portal circulation to be
metabolized, activated, or excreted in the bile, and there is evidence that xenobiotics can
modify mitochondrial proteins. Thus Long and colleagues in 2001 demonstrated that
specific organic structures attached to the mitochondrial antigens were recognized by PBC
sera with a higher affinity than the native forms of such antigens 125 suggesting that an
organic compound may serve as a mimotope for an autoantigen; one such halogenated
compound induced AMA production in rabbits with no requirement for the peptide
backbone of PDC-E2 28 albeit without producing liver lesions (possibly due to latency of
disease expression), and antibodies disappeared when the stimulus was discontinued 30. In
another study induction of PBC-like liver lesions did follow during a longer follow-up in
guinea pigs 122 while yet a further study reported two new xenobiotic-induced PBC murine
models based on the immunization of NOD.1101 123 or C57BL/6124 mice with 2-octynoic
acid. Both models illustrated breakdown of tolerance in the absence of exposure to PDC-E2
but there was no progression to liver disease. Utilizing a different approach, we next
demonstrated that 2-nonynoic acid is capable of being recognized by PBC sera with high
affinity 121, of interest since this non-naturally occurring compound is known to be found in
several cosmetic products including nail polish and their frequent use among women could
contribute to female predominant PBC 126, 127.
Cumulatively, the xenobiotic theory in PBC induction is fascinating and may well fit into
the previously illustrated view that conformational changes of self-antigens may provide an
efficient way to overcome the numerous checkpoints 128 for ‘forbidden’ clones to survive
and expand to ultimately produce the orchestrated autoimmune response based on cellular
and humoral responses 129.
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The genetics of PBC
Not mutually exclusive with regard to environmental factors leading to PBC, the challenge
to identify susceptibility gene(s) that predispose to the development of the diseases is still
open. Of interest, a most recent multi-center study reported of the first genome-wide
association study and identified interleukin 12 and its relative receptor as susceptibility
genes for PBC 130. These data were later confirmed by our group in an independent cohort
of Italian patients and controls as well as in a meta-analysis with Northern American
subjects 131. Among significantly associated genes we recapitulated the proposed
importance of HLA and STAT4 genes.
The majority of previous studies not only have been derived solely from case-control
designs 132 but were also limited by poor control matching criteria and sample size or
selection. A plethora of association studies have been conducted (reviewed elsewhere),
mainly focused on immune genes that affect the immune system belonging to both the HLA
family and non-HLA immune modulators genes, including CTLA-4, IL-1, IL-10 and
vitamin D-receptor 132, 133.
Pertinent to the individual susceptibility to PBC, several sex-related factors appear to
increase the risk of developing the disease, mostly by means of reproductive life variables.
Among these are the role of pregnancies 134, 135, contraceptives, estrogen replacement
treatments 126, and recurrent vaginitis 136 but the mechanisms remain to be elucidated.
However, the novel hypothesis of sex chromosome-related effects on PBC appears
promising 137, and may possibly operate via gene dosage or epigenetic changes 138 which
appear to be common to autoimmunity in general 139–142.
Of interest to the individual genetic susceptibility to PBC is the observation that several
animal models have been recently proposed based on a determined genetic background.
Indeed, two animal models, i.e. dnTGFβRII and IL-2Rα knockout mouse, point out the
possible crucial role of Tregs deficiency in loss of immune tolerance with consequent
development of autoimmune response against PDC-E2 in PBC. The selective deficiency of
the TGFβR-signaling pathway exclusively in T lymphocytes accounts for major
impairments of peripheral tolerance as Treg cells depend on TGFβ for their regulatory
activity, triggering the emergence of tissue-specific autoreactive effector T cells 143. A
mouse deficient for IL2 receptor α (IL-2R α), which is highly expressed on Tregs developed
100% AMA positivity against PDC-E2, 80% ANA positivity, and lymphocyte infiltration
around the portal tracts associated with cholangiocyte injury 144. These data illustrate the
important relationships between Tregs and the appearance of autoimmune portal tract
pathology and serum AMA. An additional animal model is a variant of the non obese
diabetic (NOD) mouse model (NOD.c3c4) manifesting autoimmune cholestasis and PBC-
specific serology, showing AMA positivity of 50%–60% and ANA positivity of 80%–90%.
This mouse is protected from diabetes by B6/B10 regions on chromosomes 3 and 4 that
contain B6/B10 insulin-dependent diabetes (Idd) loci. Histologically, it presents lymphocyte
infiltration around portal tracts with chronic nonsuppurative destructive cholangitis and
epithelioid granuloma formations; nevertheless, the morphological features of bile ducts
differ somewhat from those in human PBC 145. Based on these animal models we may
surmise that PBC susceptibility should be seen as a tolerance dysregulation secondary to a
permissive background (as in the NOD model) or the lack of T regulatory mechanisms (as in
the mouse deficient for IL2 receptor α on which an environmental insult could rapidly
establish an autoimmune reaction 123, 124.
One cumulative theory has been recently proposed 128 and is based on the frequency of
germline gene mutation, multiplied over the large number of known ‘tolerance/
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autoimmunity’ genes which are well illustrated in the numerous genome-wide association
studies. These would result in a high frequency of deleterious mutations in a heterozygous
state on which an autoimmune-prone phenotype could ensue either in the event of
homozygosity of one or another such genes, if a somatic mutation occurred, or via a
chromosome-specific haploinsufficiency, as well illustrated for the X chromosome 138.
Further, most autoimmune diseases manifest a striking prevalence in older ages and the
observed disease latency (in the case of PBC represented by the long latency between AMA
appearance and disease manifestations) suggests that successive mutations may need to
occur in a stepwise stochastic manner for the autoimmune phenotype to become apparent.
Similar stochastic events may take place also at different levels, including the exposure to
specific environmental factors or the interaction between different cell types in the
maintenance of immune tolerance. This is supported by most recent evidence obtained in
inflammatory bowel diseases 146 where genes and infections concur to the development of
Crohn’s disease in an animal model 147. There are multiple other environmental agents and
factors that have been incriminated in other autoimmune diseases, including the potential
role of nucleic acids as adjuvants that have not yet been studied in PBC, but which should be
addressed as possible modulators of pathology, including epigenetic influences, commensal
microbiota, nanoparticles, ultraviolet light, tobacco smoke, nutrition and stress 148–156.
Linking AMA in the pathogenesis of PBC
In contrast to classic systemic autoimmune diseases, PBC is highly tissue specific with the
cells of the small intrahepatic bile ducts as the primary target. However, apparently
paradoxically, the autoantigens of PBC, PDC-E2, OGDC-E2, and BCOADC-E2, are
ubiquitous mitochondrial proteins in all nucleated cells and hence seen as “non-traditional”
at least as compared with the “traditional” autoantigens of thyrogastric organ-specific
autoimmunity---this is possibly resolved as discussed below by the unique
immunopathological characteristics of cholangiocytes.
However, first of all, staining of small bile ducts with a panel of monoclonal antibodies
against the mitochondrial autoantigens has demonstrated that some give an intense staining
at the apical surface of the cells lining the bile duct lumen, and this is specific for PBC
liver157, 158 versus other liver pathology. This apical staining is seen only with selected
PDC-E2 specific monoclonal antibodies and that distinct epitopes could identified with such
monoclonal antibodies, leading to the hypothesis that a PDC-E2-mimicking (and thus cross-
reactive with AMA protein is recognized by the human autoantibodies 157–159. Others have
suggested that the apical staining is due to immune complexes of IgA AMA and PDC-E2
160, 161. While a solid proteomic confirmation of this critical issue is awaited, it does appear
that cholangiocytes are not just an innocent bystander in PBC pathology, but rather are
active participants. They may be involved in biliary and mucosal secretory transfer including
that of dimeric IgA 162–164. In particular, experimental data 161 suggest that PDC-E2-
specific IgA may enter bile duct cells via a poly-Ig receptor (pIgR) and complex with PDC-
E2, thereby potentially contributing to pathology. Anti-PDC-E2 IgA antibody titer in PBC
sera directly correlates with the level of caspase activation 54 and suggest that during
transcytosis through pIgR+ cells, exposure to PDC-E2-specific dimeric IgA can result in the
initiation of caspase activation. Based on the presence of dimeric AMA-IgA in biliary and
mucosal secretions 165, constant transcytosis may render the exposed cells more susceptible
to apoptosis, thus producing the bile duct damage. The apoptosis of biliary epithelial cells in
PBC warrants further discussion and may be proved to be crucial for immune tolerance
breakdown 40, 62, as illustrated in other experimental settings 166. It was first reported that
PDC-E2 remains intact and retains its immunogenicity during cholangiocyte apoptosis, due
to a cell-specific lack of glutathionylation of biliary epithelial cells 50. The intact PDC-E2 in
apoptotic fragments could be uptaken by local antigen presenting cells and transferred to
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regional lymph nodes for priming of cognate T cells thus initiating PBC. A major
contribution came from Lleo and colleagues who most recently demonstrated that PDC-E2
is found in the blebs of human intrahepatic bile duct cells undergoing apoptosis 40. More
importantly, this phenomenon was not observed in other epithelial cell lines and appears to
confirm the importance of apoptosis in the perpetuation of the autoimmune injury 62 as well
as the view that PBC bile duct cells are not unique 48. This is indeed an attractive possibility,
and data supporting such antigen presentation have been recently proposed 41 to ultimately
support that PBC autoantigens (both nuclear and mitochondrial) are indeed ‘traditional’.
Concluding remarks
Based on the data discussed, PBC can be sustained as a model autoimmune disease in which
there is loss of immune tolerance to the mitochondrially located PDC-E2 autoantigen with
the emergence of autoreactive populations of T and B lymphocytes (forbidden clones in the
old parlance). Among many likely contributors to PBC pathogenesis is a strong genetic
predisposition, not yet sufficiently dissected out, and environmental influences among which
some could determine the structure and flexibility of the autoantigen, and others (life-style
factors) could impact more on immune function itself 126. Particularly promising are current
studies on a cholangiocyte-specific form of apoptotic degradation of the PDC-E2
autoantigen which in our view could blur distinctions between the “traditional” autoantigens
of the organ-specific autoimmune diseases and the “non-traditional” autoantigens of PBC,
chiefly PDC-E2 40, 41. Further, we may expect that additional unsuspected factors will be
investigated in the pathogenesis of PBC. These may include the recently suggested
immunomodulatory effects of the gut microbiota 167 as intestinal adsorption capacity was
already found impaired in patients with PBC 168. Clearly there are many avenues still wide
open to would-be investigators of the pathogenesis of PBC.
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Figure 1.
Three-dimensional structure of the PDC-E2 inner lipoylated domain based on published
NMR structure 16
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Figure 2.
The mapping of AMA (B cell) and T cell (CD4, CD8) epitopes recognized in PBC.
Glutamic acid (E) at position 170 is highlighted for clarity purposes.
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Table 1
Molecular weights and functions of the 2-oxo-acid dehydrogenase complexes
Enzymes MW (kDa) Function
Pyruvate dehydrogenase complexes (PDC)
E1a decarboxylase 41 Decarboxylates pyruvate with thiamine pyrophosphate (TTP) as a co-
factor
E1b decarboxylase 36 Decarboxylates pyruvate with TTP as a co-factor
E2 acetyltransferase 74 Transfers acetyl group from E1 to coenzyme A (CoA)
E3 lipoamide dehydrogenase 55 Regenerates disulphide of E2 by oxidation of lipoic acid
E3 binding protein (protein X) 56 Anchoring E2 to the E2 core of pyruvate dehydrogenase complex
2-oxoglutarate dehydrogenase complex (OGDC)
E1 oxoglutarate dehydrogenase 113 Decarboxylates a-ketoglutarate with TTP as a co-factor
E2 succinyl transferase 48 Transfers succinyl group from E2 to CoA
E3 lipoamide dehydrogenase 55 Regenerates disulphide of E2 by oxidation of lipoic acid
Branched-chain 2-oxo-acid dehydrogenase
complex
(BCOADC)
E1a decarboxylase 46 Decarboxylates a-keto acids
E1b decarboxylase 38 Derived from leucine, isoleucine, and valine with TTP as a co-factor
E2 acyltransferase 52 Transfers acyl group from E1 to CoA
E3 lipoamide dehydrogenase 55 Regenerates disulphide of E2 by oxidation of lipoic acid
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